Medical-Legal-Regulatory Review (MLR) – Reviewing Pharmaceutical Communication
Contents
What is medical-legal-regulatory review?
Medical-legal-regulatory review, or MLR, is the coordinated assessment of communication material from medical, legal and regulatory perspectives. Organizations use the term for approval processes that consider statements, audiences and intended use.
MLR is not a globally uniform statutory procedure. Its organization depends on the country, product type and internal responsibilities. What matters is that the necessary assessments are performed by qualified people and documented clearly.
Why is MLR relevant to pharmaceutical communication?
A statement may be scientifically supported while remaining misleading or inappropriate in its intended promotional context. Equally, a legally cautious phrase may describe the medical evidence inaccurately. Coordinated review brings these perspectives together.
Assessment should cover images, diagrams, footnotes, destination pages and the planned channel as well as the main text. Their combination shapes the message received by the audience. A review that considers wording alone may miss that overall effect.
How should a traceable review be organized?
A useful process starts before the final layout and establishes the information reviewers need.
- Briefing: Identify the product, market, audience, purpose and intended use of the material.
- Evidence: Connect statements with appropriate references and relevant approved product information.
- Assessment: Resolve comments, decisions and outstanding issues under clear responsibilities.
- Approval: Record the version, scope, conditions and triggers for further review.
Changes should be classified so that teams can distinguish a presentation adjustment from a change in meaning or intended use. This supports proportionate but defensible review decisions.
What challenges commonly arise?
Incomplete submissions and conflicting comments can create avoidable delays. Shared criteria, reasoned feedback and early discussion can help. Approval quality should not be assessed solely through turnaround time.
Responsibility continues after approval. New safety information, changed references or a different audience may require reassessment. Approved components also remain subject to the context and conditions in which they were reviewed. A software status cannot substitute for a professional decision or demonstrate that the material is being used as intended.
What do Medical, Legal and Regulatory actually assess?
The organization defines the exact responsibilities. Typical questions include:
- Medical: Does the study support the claim, with population, comparator and uncertainty accurately represented?
- Legal: Is the message permissible in this advertising context and for this audience?
- Regulatory: Do product status, indication and details match the relevant product information?
A chart may involve all three perspectives. Decisions therefore need to align; three isolated check marks are insufficient.
Conclusion: Connect perspectives and document decisions
MLR makes review responsibilities and approval decisions traceable. Its value lies in assessing evidence, the communication itself and its intended use together. Clear briefs and controlled changes help combine professional quality with workable collaboration.
